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Over the last 5 years, a number of outbreaks of measles have 
occurred in several European Union (EU) countries. Many of 
these outbreaks continue and/or continued for more than 1 year 
after the notification of the first case. Curiously in many of measles 
outbreaks about 10% of the patients were less than 12 months of 
age. All these patients according to the current EU countries vac-
cination calendars were not yet vaccinated against measles. Based 
on the results of measles outbreaks, especially age of affected 
patients, we should consider changing measles vaccination sched-
ules in all EU countries. Most of mothers between 30 and 40 years 
of age are not vaccinated against measles, and many of them are 
not naturally immune against measles. These mothers do not pose 
antibodies against measles and in turn do not provide vertical 
protection for their infants. In conclusion, administrating the first 
dose of measles vaccine in the EU countries should be considered 
before 12 months of age, most probably at 9 months of age.
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Summary
Measles is a highly infectious disease caused by the vi-
rus paramyxovirus, which is a linear single strand RNA. 
Measles was first described by Abu Becr Rhazes in the 
10th century as Hasbah, which means eruption in Ara-
bic. Since then measles epidemics continue to occur, 
with inter-epidemic periods of 3-5 years [1, 2]. This has 
been substantially changed since the inclusion of mea-
sles vaccine in the obligatory vaccine calendar in all 
European Union (EU) countries about 30 years ago. All 
EU countries included two doses of measles vaccine, 
with the first dose between 12 and 18 months of age [2, 
3]. Previous studies showed that measles vaccine when 
given in two doses, at least 98% of vaccine recipients 
develop protective immunity against the disease [2]. In 
concordance, epidemiological investigation of a mea-
sles outbreak in a preschool in Incheon (Korea) showed 
that measles vaccine efficacy was 88.8% in the one dose 
group and 98% in the two doses group. The authors rec-
ommended improving the coverage with two doses vac-
cination [4].
Over the last 5 years, a number of outbreaks of mea-
sles have occurred in several EU countries [5]. Many 
of these outbreaks continue and/or continued for more 
than 1 year after the notification of the first case. One 
of the explanations for these outbreaks was the pres-
ence of non-vaccinated population over 30 years of 
age. Another explanation was vaccination rejection 
by several sectors of the population; anthroposophic, 
and ultra-orthodox Jewish communities, and immi-
grants [2, 6].
Curiously in many of measles outbreaks about 10% of 
the patients were less than 12 months of age. All these 
patients according to the current EU countries vacci-
nation calendars were not yet vaccinated against mea-
sles [2, 3]. 
Old studies on measles infection showed that infants 
were protected against measles with maternal antibodies 
over the first year of their lives. Vaccination of infants 
after 12 months of age aimed at avoiding the neutraliz-
ing effect of maternal antibodies and in turn improving 
measles vaccine effectiveness [7]. Based on the results 
of measles outbreaks, especially age of affected patients, 
we should consider changing measles vaccination sched-
ules in all EU countries. It is necessary to administrate 
the first dose of measles vaccine below 12 months of 
age, for example at 9 months of age, because of several 
reasons. 
First, most of mothers between 30 and 40 years of age 
are not vaccinated against measles, and many of them 
are not naturally immune against measles. These moth-
ers do not pose antibodies against measles and in turn do 
not provide vertical protection for their infants [3, 7]. In 
concordance with this observation, a recent study con-
ducted in Sheffield (UK) evaluated the risk of health-
care workers (HCWs) of contracting and transmitting 
measles and mumps to patients and staff. To examine 
this risk at the point of entry to healthcare, the authors 
assessed the serological results of new HCWs presenting 
for pre-placement clearance without evidence of mea-
sles-mumps-rubella (MMR) immunity between 1 April 
2010 and 31 March 2012. Overall rates of serological 
positivity to MMR across all age groups were 88.2%, 
68.8% and 93.9%, respectively. With regard to measles 
and mumps, there were statistically significant decreas-
es in the percentage of HCWs born after 1980 that had 
positive serology (P < 0.05) [5].
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Second, over the last 30 years the prevalence of measles 
infections in the EU countries was progressively lower-
ing. The contact of vaccinated women between 30 and 
40 years of age was almost negligible. This contact acts 
like a booster dose and stimulates the immunity systems 
to generate measles antibodies. Again vaccinated moth-
ers aged between 30 and 40 years old provide very low 
levels of antibodies to their infants, not sufficient to pro-
tect them over the first 12 months of their lives [2, 7]. 
Third, the prevalence of breast feeding is lowering or at 
least reduced in duration all over the EU countries, espe-
cially over the last 20 years because of several social and 
economic changes. Maternal milk provides antibodies 
which offers major protection for infants against many 
bacterial and viral infections including measles [1, 8]. 
The recent vaccine calendar of the Spanish Association 
of Paediatrics (2013) recommended administration of 
the first dose of measles vaccine at 12 months of age, 
not at 15 months as recommended before. The second 
dose is recommended between 2 and 3 years of age to 
achieve a protection > 98% [9]. 
In conclusion, administrating the first dose of measles 
vaccine in the EU countries should be considered before 
12 months of age, most probably at 9 months of age. 
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